Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Gets $600K From US DoD to Ramp up COVID-19 Test Kit, Reagent Manufacturing

NEW YORK – The US Department of Defense said on Monday that it has awarded a $600,000 contract to Qiagen to expand manufacturing capacity of enzymatic reagents and reagent kits used in COVID-19 molecular diagnostic tests.

The contract, awarded on behalf of and in conjunction with the US Department of Health and Human Services, will allow Qiagen to increase its monthly production of reagent kits by 7,000 and enzymes by 5,100 milligrams in its Beverly, Massachusetts, facility by the end of February 2022 to support domestic laboratory testing for COVID-19.

The current manufacturing capacity of Qiagen's Beverly facility is unknown. An email to the company was not immediately returned.

The DoD's Defense Assisted Acquisition Cell, or DA2, led this effort in coordination with the Department of the Air Force's Acquisition COVID-19 Task Force, or DAF ACT.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.